Form 4: REVB Director Sells Shares for Tax Obligations

Revelation Biosciences Director Jennifer Carver sold 1,661 shares of common stock to cover tax liabilities from restricted stock vesting, following a 1-for-4 reverse stock split.

Summary

• Jennifer Carver, a Director at Revelation Biosciences, Inc. (REVB), reported a transaction involving the sale of common stock.
• The transaction occurred on February 3, 2026, and involved the disposition of 1,661 shares of common stock.
• The shares were sold at a weighted average price of $1.87 per share, with individual transactions ranging from $1.87 to $1.88.
• This sale was mandatory and solely to satisfy required tax obligations arising from the vesting of restricted stock awards.
• The reporting person did not exercise investment discretion regarding this sale.
• Following the transaction, Jennifer Carver beneficially owns 12,758 shares of Revelation Biosciences common stock.
• All share numbers reflect a 1-for-4 reverse stock split that became effective on January 28, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While any insider selling can raise questions, the mandatory nature of this sale for tax purposes, following a reverse stock split, indicates a routine compensation-related transaction rather than a discretionary move signaling a lack of confidence.

Negatives

• A director selling shares, even for tax purposes, can sometimes be perceived by the market as a lack of confidence, though this specific transaction is non-discretionary.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Shares were sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards.
• The transaction was mandatory, and the reporting person did not exercise investment discretion with respect to the sale.

Industry Context

StockSavvy.ai notes that mandatory sales of shares by executives and directors to cover tax obligations upon the vesting of restricted stock awards are a common and routine occurrence across all industries. Such transactions are typically not indicative of management's sentiment towards the company's future prospects, unlike discretionary sales.

Comparison to Industry Standards

• This type of transaction, a non-discretionary sale of shares to cover tax liabilities from equity compensation, is a standard occurrence for executives and directors across publicly traded companies globally.
• It does not provide a basis for specific comparisons to company performance, projects, or results of comparable companies, as it is a personal financial event tied to compensation structure rather than operational outcomes.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of outstanding shares but is a routine event for equity compensation.
• Employees: No direct impact mentioned, but it reflects standard executive compensation practices.

Key Dates

Recommendation

The transaction is a mandatory, non-discretionary sale of shares by a director to cover tax obligations from restricted stock vesting. This is a routine event and does not provide a strong signal for either buying or selling the stock. Investors should hold and monitor for more substantive operational or strategic news.

Keywords

Revelation Biosciences, REVB, Form 4, Insider Trading, Director Share Sale, Restricted Stock, Tax Obligations, Reverse Stock Split